Quick Answer
Outlook Therapeutics, Inc. reported Diluted EPS of $1.79 per share (loss) for fiscal year 2025.
Outlook Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.79 | +55.9% |
| 2024 | -$4.06 | +14.0% |
| 2023 | -$4.72 | -1422.6% |
| 2022 | -$0.31 | +11.4% |
| 2021 | -$0.35 | +47.8% |
| 2020 | -$0.67 | +45.1% |
| 2018 | -$1.22 | +32.2% |
| 2017 | -$1.80 | +51.0% |
| 2016 | -$3.67 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.38 | -152.8% | +30.9% |
| June 30, 2025 | -$0.55 | +38.2% | +63.3% |
| March 31, 2025 | -$1.50 | +81.3% | -308.3% |
| December 31, 2024 | $0.72 | +183.7% | +180.9% |
| June 30, 2024 | -$0.89 | +44.7% | +88.9% |
| March 31, 2024 | -$8.01 | -1440.4% | -831.4% |
| December 31, 2023 | -$0.86 | -975.0% | +46.6% |
| June 30, 2023 | -$1.61 | -1912.5% | -209.6% |
- Outlook Therapeutics, Inc. showed an increase of +55.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, Outlook Therapeutics, Inc.’s diluted eps has grown by 51.2% (from $3.67 per share (loss) to $1.79 per share (loss)).
- The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: